Proposed amendments to the EU’s supplementary protection certificate manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations.
The University of Wisconsin’s licensing arm has been ordered to pay Washington University $31.6 million in a fight over patent licensing relating to one of AbbVie’s kidney drugs.
The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.
The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.
Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark
California-based FlexStent accused healthcare company Abbott Laboratories of infringing a stent patent earlier this week, with the filing of a lawsuit at the US District Court for the Central District of California.
The US Food and Drug Administration is set to change the way that medical devices are approved, after 42 years.
Despite the importance of IP rights to biotech and biopharma innovation, recent decisions and new policies are weakening and reducing the scope of IP-based incentives, according to a report.
India-based drug company Sun Pharma has made further inroads into the Japanese market with the planned acquisition of Pola Pharma.
The EU General Court dismissed Canada-based Endoceutics’ trademark appeal in a win for medical technology company Merck KGaA on Thursday, November 22.